EASTERN BANK Boosts Johnson & Johnson Stake with 153,938 Share Addition

EASTERN BANK has significantly increased its stake in Johnson & Johnson (JNJ) by adding 153,938 shares to its portfolio, according to a recent SEC 13F filing. This move reflects the fund's holdings as of September 30, 2026. The addition is part of a broader trend where institutional investors have shown renewed interest in JNJ, with 2,184 institutions adding shares and 1,991 reducing their positions in the latest quarter.

Among the notable institutional moves, JPMORGAN CHASE & CO added 58,301,609 shares, while SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. increased its holdings by 19,126,165 shares. Conversely, GQG PARTNERS LLC and DIAMANT ASSET MANAGEMENT, INC. significantly reduced their positions, removing 7,292,131 and 4,454,805 shares, respectively.

Johnson & Johnson's insiders have also been active, with 11 sales and no purchases made in the past six months. CEO Joaquin Duato sold the most shares, totaling 171,771 worth an estimated $44,714,937. Other executives, including Timothy Schmid and Vanessa Broadhurst, also made notable sales.

The company received $37,347,470 in government contract awards over the past year, with the largest awards going to medical devices like the VOLT(TM) STRAIGHT PLATE and VA LOCKING HAND INSTRUMENT. Additionally, members of Congress have traded JNJ stock six times in the last six months, with Representative Thomas H. Kean, Jr. making three sales.

Analysts have set various price targets for JNJ, with a median target of $265.0. Recent targets include $298.0 from Joanne Wuensch at Citigroup and $284.0 from Terence Flynn at Morgan Stanley. These estimates highlight the ongoing interest and speculative activity surrounding the stock.